Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1803 1
1844 1
1845 4
1846 3
1847 1
1850 2
1852 1
1853 2
1854 2
1855 1
1856 2
1861 1
1862 1
1867 1
1878 1
1884 1
1888 1
1889 1
1901 1
1905 1
1910 1
1911 1
1912 4
1913 3
1914 1
1915 3
1916 3
1917 8
1918 3
1919 1
1920 2
1921 6
1922 3
1923 3
1925 1
1926 4
1927 1
1930 1
1932 1
1936 1
1938 2
1939 2
1940 1
1942 1
1944 2
1945 1
1946 6
1947 6
1948 13
1949 19
1950 20
1951 20
1952 15
1953 31
1954 27
1955 22
1956 34
1957 17
1958 21
1959 19
1960 18
1961 14
1962 18
1963 19
1964 25
1965 35
1966 29
1967 43
1968 40
1969 44
1970 50
1971 50
1972 65
1973 60
1974 54
1975 79
1976 68
1977 65
1978 82
1979 60
1980 57
1981 64
1982 55
1983 75
1984 89
1985 91
1986 90
1987 79
1988 107
1989 105
1990 135
1991 121
1992 128
1993 97
1994 109
1995 118
1996 135
1997 119
1998 126
1999 135
2000 153
2001 153
2002 151
2003 179
2004 186
2005 191
2006 198
2007 212
2008 195
2009 203
2010 232
2011 287
2012 284
2013 340
2014 315
2015 321
2016 380
2017 388
2018 360
2019 332
2020 351
2021 401
2022 406
2023 356
2024 235

Text availability

Article attribute

Article type

Publication date

Search Results

9,414 results

Results by year

Filters applied: . Clear all
Page 1
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin.
Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, Søgaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yıldız-Altay Ü, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Tang Q, et al. Among authors: harris je. Nat Commun. 2023 Nov 4;14(1):7099. doi: 10.1038/s41467-023-42714-4. Nat Commun. 2023. PMID: 37925520 Free PMC article.
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, Waxman AJ, Chong ER, Patel V, Pajarillo R, Kulikovskaya I, Lieberman DB, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Hexner EO, Barta SK, Porter DL, Garfall AL, Schuster SJ, June CH, Ruella M. Ghilardi G, et al. Among authors: harris jc. Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24. Nat Med. 2024. PMID: 38266761
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations.
Seneschal J, Speeckaert R, Taïeb A, Wolkerstorfer A, Passeron T, Pandya AG, Lim HW, Ezzedine K, Zhou Y, Xiang F, Thng S, Tanemura A, Suzuki T, Rosmarin D, Rodrigues M, Raboobee N, Pliszewski G, Parsad D, Oiso N, Monteiro P, Meurant JM, Maquignon N, Lui H, Le Poole C, Leone G, Lee AY, Lan E, Katayama I, Huggins R, Oh SH, Harris JE, Hamzavi IH, Gupta S, Grimes P, Goh BK, Ghia D, Esmat S, Eleftheriadou V, Böhm M, Benzekri L, Bekkenk M, Bae JM, Alomar A, Abdallah M, Picardo M, van Geel N. Seneschal J, et al. Among authors: harris je. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2185-2195. doi: 10.1111/jdv.19450. Epub 2023 Sep 15. J Eur Acad Dermatol Venereol. 2023. PMID: 37715487
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm.
van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, Passeron T, Wolkerstorfer A, Abdallah M, Alomar A, Bae JM, Bekkenk M, Benzekri L, Böhm M, Eleftheriadou V, Esmat S, Ghia D, Goh BK, Grimes P, Gupta S, Hamzavi IH, Harris JE, Oh SH, Huggins R, Katayama I, Lan E, Lee AY, Leone G, Le Poole C, Lui H, Maquignon N, Meurant JM, Monteiro P, Oiso N, Parsad D, Pliszewski G, Raboobee N, Rodrigues M, Rosmarin D, Suzuki T, Tanemura A, Thng S, Xiang F, Zhou Y, Picardo M, Seneschal J. van Geel N, et al. Among authors: harris je. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2173-2184. doi: 10.1111/jdv.19451. Epub 2023 Sep 25. J Eur Acad Dermatol Venereol. 2023. PMID: 37746876
Exploring the anti-inflammatory activity of sulforaphane.
Treasure K, Harris J, Williamson G. Treasure K, et al. Among authors: harris j. Immunol Cell Biol. 2023 Oct;101(9):805-828. doi: 10.1111/imcb.12686. Epub 2023 Aug 31. Immunol Cell Biol. 2023. PMID: 37650498 Review.
Circulating proteins to predict COVID-19 severity.
Su CY, Zhou S, Gonzalez-Kozlova E, Butler-Laporte G, Brunet-Ratnasingham E, Nakanishi T, Jeon W, Morrison DR, Laurent L, Afilalo J, Afilalo M, Henry D, Chen Y, Carrasco-Zanini J, Farjoun Y, Pietzner M, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Moussa Y, DeLuca C, Duggan N, Schurr E, Brassard N, Durand M, Del Valle DM, Thompson R, Cedillo MA, Schadt E, Nie K, Simons NW, Mouskas K, Zaki N, Patel M, Xie H, Harris J, Marvin R, Cheng E, Tuballes K, Argueta K, Scott I; Mount Sinai COVID-19 Biobank Team; Greenwood CMT, Paterson C, Hinterberg MA, Langenberg C, Forgetta V, Pineau J, Mooser V, Marron T, Beckmann ND, Kim-Schulze S, Charney AW, Gnjatic S, Kaufmann DE, Merad M, Richards JB. Su CY, et al. Among authors: harris j. Sci Rep. 2023 Apr 17;13(1):6236. doi: 10.1038/s41598-023-31850-y. Sci Rep. 2023. PMID: 37069249 Free PMC article.
Blood Product Safety.
Harris JC, Crookston KP. Harris JC, et al. 2023 Mar 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Mar 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30969648 Free Books & Documents.
A Response to Zambrano.
Harris J. Harris J. Camb Q Healthc Ethics. 2023 Jan;32(1):134-137. doi: 10.1017/S0963180122000561. Epub 2022 Dec 12. Camb Q Healthc Ethics. 2023. PMID: 36503592
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.
Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, Wong SJ, Koyfman SA, Dzeda MF, Clump DA, Khan SA, Shah MH, Redmond K, Torres-Saavedra PA, Le QT, Lee NY. Sherman EJ, et al. Among authors: harris j. Lancet Oncol. 2023 Feb;24(2):175-186. doi: 10.1016/S1470-2045(22)00763-X. Epub 2023 Jan 18. Lancet Oncol. 2023. PMID: 36681089 Free PMC article. Clinical Trial.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Nassar AH, et al. Among authors: harris jp. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. J Thorac Oncol. 2024. PMID: 38278303
9,414 results